Company profile
TransThera Sciences (Nanjing), Inc.
2617 · HKEX (Chinese clinical-stage biotech (formerly Nanjing TransThera Biosciences) that IPO'd on the Hong Kong Stock Exchange Main Board under Chapter 18A on June 23, 2025, trading as 2617.HK. Not present in the existing roster (no company_id match), so left unmatched rather than forced onto an unrelated row. Sources: https://clinicaltrials.gov/study/NCT04742959 ; https://api.gleif.org/api/v1/lei-records/836800110GC58JARGW44 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://www.sidley.com/en/newslanding/newsannouncements/2025/06/sidley-advises-on-the-successful-hong-kong-ipo-of-transthera-sciences ; https://finance.yahoo.com/quote/2617.HK/ Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for TransThera Sciences (Nanjing), Inc. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Small molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.